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ABSTRACT Structures of the blood clotting enzyme thrombin complexed with hirugen and two active site inhibitors,
RWJ-50353 1 0080(N-methyl-D-phenylalanyl-N-[5-[(aminoiminomethyl)amino]-1
-[[(2-benzothiazolyl)carbonyl]butyl]-L-pro-
linamide trifluoroacetate hydrate) and RWJ-50215 (N-[4-(aminoiminomethyl)amino-1 -[2-(thiazol-2-ylcarbonylethyl)piperidin-
1 -ylcarbonyl]butyl]-5-(dimethylamino)naphthalenesulfonamide trifluoroacetate hydrate), were determined by x-ray crystallog-
raphy. The refinements converged at R values of 0.158 in the 7.0-2.3-A range for RWJ-50353 and 0.155 in the 7.0-1.8-A
range for RWJ-50215. Interactions between the protein and the thiazole rings of the two inhibitors provide new valuable
information about the Si' binding site of thrombin. The RWJ-50353 inhibitor consists of an Sl'-binding benzothiazole group
linked to the D-Phe-Pro-Arg chloromethyl ketone motif. Interactions with the S1-S3 sites are similar to the D-phenylalanyl-
prolyl-arginyl chloromethylketone structure. In RWJ-50215, a Si'-binding 2-ketothiazole group was added to the thrombin
inhibitor-like framework of dansylarginine N-(3-ethyl-1,5-pentanediyl)amide. The geometry at the S1-S3 sites here is also
similar to that of the parent compound. The benzothiazole and 2-ketothiazole groups bind in a cavity surrounded by His57,
Tyr60A, Trp6OD, and Lys6OF. This location of the S1' binding site is consistent with previous structures of thrombin
complexes with hirulog-3, CVS-995, and hirutonin-2 and -6. The ring nitrogen of the RWJ-50353 benzothiazole forms a
hydrogen bond with His57, and Lys6OF reorients because of close contacts. The oxygen and nitrogen of the ketothiazole of
RWJ-50215 hydrogen bond with the NZ atom of Lys6OF.
INTRODUCTION
The serine protease thrombin plays an important and central
role in blood coagulation (Davie et al., 1991). Its most
prominent function is the conversion of fibrinogen to fibrin
(Blomback et al., 1967; Hogg and Blomback, 1978). Poly-
merization of the resulting monomers and cross-linking by
factor XIII lead to formation of a fibrin network and an
insoluble blood clot. Thrombin also activates factor V and
factor VIII (Jackson and Nemerson, 1980), and stimulates
platelet aggregation and secretion (Hung, et al., 1992). It
additionally activates other coagulation proenzymes and is
involved in anticoagulation processes by the activation of
protein C (Esmon et al., 1982; Esmon, 1989).
A large number of thrombin-inhibitor complexes have
been studied by x-ray crystallography (Stubbs and Bode,
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1993; Tulinsky and Qiu, 1993; Mathews et al., 1994;
Mathews and Tulinsky, 1995; Krishnan et al., 1996). These
structures have increased our understanding of the many
important roles that thrombin plays and have revealed a
wide variety of binding modes and geometries for the en-
zyme. Most of the inhibitors bind to one or the other of the
S1-S3 subsites of the active site and/or the fibrinogen
recognition exosite.
Less is known about binding at the S' sites. The impor-
tance of these regions was originally established by binding
studies of fibrinopeptide A fragments, which showed that
the presence of P3'-P4' residues lowered Kd by an order of
magnitude (Marsh et al., 1983). Binding at S' subsites of
thrombin was first revealed by the structure of the thrombin
complex with hirulog 3, a synthetic divalent peptide with
both active site and exosite binding moieties that are linked
with a pentaglycine spacer to a nonhydrolyzable p-ho-
moarginine at P1 (Qiu et al., 1992). The P1' glycine occu-
pies a small cavity surrounded by His57, Tyr6OA, Trp6OD,
and Lys6OF; forms hydrogen bonds to Lys6OFNZ,
Serl950G, and His57NE2 (Fig. 1); and adopts a conforma-
tion that would be disallowed for residues with side chains.
These observations are in agreement with the preference for
smaller residues like glycine and serine at the P1' position
of natural thrombin substrates. Following a bend at the P1'
residue, the remainder of the spacer and most of the C-
terminal hirudin-like fragment, hirugen, are in an extended
conformation. Binding to the enzyme involving main-chain
atoms occurs at the S2'-S4' subsites. Vacant space in the
region of thrombin near these sites suggests that residues
with side chains could enhance binding.
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thrombin (Bode et al., 1990; Turk et al., 1991). The x-ray
structure determination of DAPA complexed with thrombin
was similar, showing a binding mode with likenesses to
both substrates and hirudin: the P2 dansyl and P1' piperi-
dine groups of DAPA bind in the S3 and S2 subsites,
respectively, whereas the P1 arginine forms an ion pair with
Aspl89 (Mathews and Tulinsky, 1995).
MATERIALS AND METHODS
16 150
9-1189
FIGURE 1 Overall view of the C,, structure of thrombin. Pertinent
active-site side chain in bold. N-terminals of two chain thrombin are
numbered (ID, 16). Gly150 is N-terminal after autolysis loop.
An a-ketoamide group, stable to thrombin cleavage, links
the P1 arginine to the pentaglycine spacer in a related class
of divalent inhibitors (Krishnan et al., 1996). The x-ray
crystal structure of the thrombin complex of one of these
molecules, CVS995, shows many of the same S' interac-
tions. Other comparable divalent inhibitors, called hiru-
tonins, have been developed where cleavage of the scissile
bond is prevented by replacing the nitrogen of the amide
with a methylene group (DiMaio et al., 1992). In thrombin
complexes of hirutonin-2 and hirutonin-6 (Zdanov et al.,
1993), molecules with linkers of different length, the inhib-
itors follow pathways through the S' binding regions similar
to hirulog 3 and CVS995.
We report here the crystallographic results of inhibitors
of thrombin with SI'-binding, thiazole-containing groups
attached to PPACK and DAPA-like frameworks (Fig. 2)
and discuss implications for the future design of inhibitors.
The potent inhibitor RWJ-50353 (Fig. 2), with a Ki value of
0.16 nM, resembles the PPACK molecule (Bode et al.,
1992), except that the chloromethyl group is replaced with
a 2-benzothiazole group. The other molecule, RWJ-50215
(Fig. 2), inhibits thrombin with a Ki value of 1.2 ,uM and is
related to DAPA, an early member of a well-known class of
inhibitors based on the chemical nature of thrombin binding
sites (Fig. 2) (Okamoto et al., 1976; Hijikata et al., 1976;
Nesheim et al., 1979). X-ray crystal structures related to the
latter include complexes of human thrombin with NAPAP
and argatroban (MQPA, MD-805) at 3.0 A resolution (Ban-
ner and Hadvary, 1991), and bovine s-thrombin complexed
with NAPAP, 4-TAPAP, and argatroban determined at 2.3
A (Brandstetter et al., 1992). The structures of some of the
inhibitor complexes were first determined with trypsin, and
the coordinates were used to generate models of binding to
Crystallization
The RWJ-50353 and RWJ-50215 inhibitors were synthesized and purified
to homogeneity by reverse-phase high-performance liquid chromatography
at the R. W. Johnson Pharmaceutical Research Institute (Spring House,
PA). Microanalytical data support trifluoroacetate hydrates; percentages of
C, H, N and H20 were within 0.5% of theory. Details of the synthesis and
biological activity will be published elsewhere.
Both compounds were used without further purification. An approxi-
mately 10-fold molar excess of hirugen was first added to a frozen l-ml
sample of human a-thrombin solution (1.06 mg/ml in 0.75 M NaCl) at 4°C
and allowed to thaw to form the complex and prevent autolysis. The ternary
complexes were prepared by adding the RWJ inhibitors in 10-15-fold
molar excess to the hirugen-thrombin complex. The solutions of the com-
plexes were diluted to 2 ml with 0.1 M phosphate buffer at pH 7.3 and
concentrated to about 5 mg/ml by using a Centricon 10 miniconcentrator
(MW cutoff 10K) in a refrigerated centrifuge. Crystallization was carried
out in 10-,l hanging drops against 1 ml of well solution containing 0.1 M
phosphate buffer, pH 7.3, and 27-28% PEG 8000 as previously described
(Skrzypczak-Jankun et al., 1991).
Intensity data collection
The RWJ-50353-hirugen-thrombin ternary complex crystal x-ray diffrac-
tion data were collected with a Siemens multiwire X-1000 area detector
mounted on a Siemens P3/F four-circle goniostat. Graphite monochro-
mated CuKa radiation was generated by a Rigaku RU200 rotating anode
source at 7.5-kW power. The crystal-to-detector distance was set at 11.65
cm. The detector swing angle was -15°, the scan range was 0.2°/frame,
and each frame was collected for 90 s. The program XENGEN (Howard et
al., 1987) was used to process the data to obtain integrated intensities. The
crystal diffracted x rays to 2.3-A resolution with an average peak width of
0.60.
The RWJ-50215-hirugen-thrombin intensities were measured with an
R-AXIS II imaging plate detector and graphite monochromated CuKa
radiation from a Rigaku RU200 rotating anode generator, using a fine focus
filament (0.3 x 0.3 mm) with a power setting of 5 kW. The crystal-to-
detector distance was 75.1 mm, and the crystal diffracted x rays to 1.8-A
resolution. The unit cell dimensions were determined by autoindexing
(Higashi, 1990), and the processing of the raw data was carried out with the
Rigaku R-AXIS data-processing software package. Both crystals are
monoclinic, space group C2, four complexes per unit cell, with a = 70.79
A, b = 72.53 A, c = 73.12 A,3 = 101.0 for RWJ-50353, and a -71.47,
b = 72.00, c = 73.39 A, ,8 = 101.130 for RWJ-50215 (Vm = 2.4 A3/Da,
protein fraction 51%). The crystals of the RWJ-50353 and RWJ-50215
complexes are isomorphous with hirugen-thrombin and other crystals of
binary (Qiu et al., 1992; Krishnan et al., 1996) and ternary complexes
(Mathews and Tulinsky, 1995) of thrombin. For the RWJ-50353-thrombin
complex, a total of 15,300 independent measurements were obtained from
48,511 collected measurements. Removing weak data with I/sigma(I) < 2
produced a data set of 14,479 unique reflections (75% observed, Rmerge
(IF12) = 0.054). This data set is complete to 2.5-A resolution and contains
half of the possible reflections between 2.5-A and 2.3-A resolution. After
the R axis data recorded from RWJ-50215-thrombin were processed,
23,968 independent reflections were obtained from a total of 52,463
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FIGURE 2 Active-site inhibitors of thrombin. RWJ 50353, RWJ 50215 inhibitors in this work. Numbering and nomenclature are as used in text.
observations (20,391 independent reflections after removal of observations
with I < 2 sigma(l); Rmer e on Fl2 = 0.052; 80.4% completion at 2.5 A;
69.5% completion at 1.8 A).
Structure determination and refinement
The positional and thermal parameters were refined by restrained least-
squares methods using the program PROFFT (Hendrickson, 1985; Finzel,
1987). To simplify the dictionary restraints of RWJ-50215, it was treated
as four parts (Dan, Arg, Pip, Tzl; Fig. 2).
The phases of the RWJ-50353 and RWJ-50215 complexes were ap-
proximated using the thrombin coordinates of the thrombin-hirugen and
DAPA-thrombin-hirugen complexes, respectively. The initial crystallo-
graphic R-factors were about 0.30 and reduced to 0.20-0.21 after 15-18
cycles of refinement. The first (2IFOI-lFcl) electron density maps from
7.0-2.8-A resolution showed density for most of the thrombin molecule,
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with hirugen in the fibrinogen-binding exosite. All of the RWJ-50353 and
most of the RWJ-50215 inhibitor were located in the first round of
refinement. The linker group between the piperidine and thiazole rings of
RWJ-50215 fits the electron density much better when the C2 atom of the
piperidine is in the R-configuration rather than when S-stereochemistry is
modeled.
The electron density of the thrombin complexes was compatible with
two possible orientations of the benzothiazole (RWJ-50353) and thiazole
(RWJ-50215) rings in which the positions of the nitrogen and sulfur atoms
are approximately interchanged. The correct position of the sulfur atom of
the benzothiazole group was determined by 1) refining in the two possible
positions and examining the temperature factors of the sulfur atom, 2)
occupancy refinement of the sulfur atom in each position, and 3) examining
the possible interactions of the benzothiazole group with thrombin. The
first strategy did not produce conclusive results; however, the occupancy
refinement clearly established the correct position of the sulfur atom. The
occupancy factor of the sulfur (starting at 0.75) increased to 0.86, but
decreased to 0.50 in the alternate position. A hydrogen bond (2.7 A)
between the N3 atom of the benzothiazole group and His57NE2 of throm-
bin further supported the conclusion of the occupancy refinements. The
position of the nitrogen atom of a benzoxazole group of a porcine elastase
inhibitor makes a similar hydrogen bond with His57NE2 (Edwards et al.,
1992).
With RWJ-50215, two independent refinements were carried out on
models rotating the thiazole ring approximately 1800 with nitrogen atoms
at both heteroatom positions. The refinements of both converged with
higher occupancy factors for the same nitrogen position. This assignment
places the nitrogen in position to form a good hydrogen bond with the NZ
atom of Lys 60F (3.0 A), which is a more chemically reasonable alternative
than having the ring sulfur atom make the interaction.
An important structural transition of thrombin has been identified when
sodium ion binding to the enzyme induces a conformational change from
a slow to a fast kinetic form (Ayala and DiCera, 1994). The physiological
sodium ion site was first established crystallographically by rubidium ion
exchange (DiCera et al., 1995). Since then, an intermolecular sodium ion
binding site has been identified to be common to isomorphous hirugen
thrombin complexes crystallizing in space group C2 (unpublished results
of this laboratory). Both RWJ-50353 and RWJ-50215 thrombin complexes
crystallize in this space group, and each has two sodium ions with occu-
pancies of about 0.85.
The final refinement reached convergence with an R value of 0.158 in
the 7.0-2.3-A resolution range, for the RWJ-50353 complex using 143
water molecules with an occupancy of >0.5 and B < 45 A2 ((B) = 28 A2);
the RWJ-50215 complex converged at an R value of 0.155 in the 7.0-1.8-A
resolution range, 161 water molecules with an occupancy of >0.5 and B <
40 A2 ((B) = 26 2)
The omega angles of 97% of the peptide bonds of thrombin are within
60 of planarity, and the distribution of main-chain torsion angles of the
complexes shows that all of the nonglycine amino acids fall within or close
to the allowed regions in the Ramachandran map. The results from the final
refinement cycles are listed in Table 1; they show that the deviations from
ideal geometry are comparable for the two structures.
RESULTS AND DISCUSSION
Thrombin
The thrombin structures of the two inhibitor complexes
have an rms difference of 0.35 A when their CA atoms are
superposed. The thrombin structure (Fig. 1) shows no large
differences from other isomorphous inhibitor complexes;
the CA positions of the RWJ-50353 and RWJ-50215 struc-
tures have an rms difference of 0.19 A and 0.32 A compared
to monoclinic PPACK-thrombin complex (Vijayalakshmi et
al., 1994) and an rms difference of 0.33 A and 0.22 A
TABLE I Target values and deviations of refinement
parameters from idealized geometry
rms deviations
Target values RWJ-50353 RWJ-50215
Distances
Bond distance (A) 0.015 0.015 0.016
Angle distance (A) 0.030 0.044 0.042
Planar 1-4 distance (A) 0.045 0.054 0.051
Miscellaneous
Plane groups (A) 0.030 0.030 0.032
Chiral centers (A3) 0.15 0.21 0.21
Nonbonded distances
Single torsion (A) 0.60 0.22 0.19
Multiple torsion (A) 0.60 0.31 0.21
Possible X-Y H-bond (A) 0.60 0.28 0.25
Torsion angles
Planar (deg) 3 4 4
Staggered (deg) 15 20 20
Orthonormal (deg) 20 30 30
Thermal restraints
Main-chain bond (A2) 1.0 1.1 1.1
Main-chain angle (A2) 1.5 1.9 1.8
Side-chain bond (A2) 2.0 2.6 2.8
Side-chain angle (A2) 2.5 3.8 4.1
compared to the DAPA
and Tulinsky, 1995).
complex, respectively (Mathews
Inhibitors
The active-site inhibitors have a well-defined electron den-
sity (Fig. 3). The binding of the inhibitors follows the two
major modes of thrombin active site binding exemplified by
the PPACK and argatroban/DAPA types, respectively. The
PPACK class of inhibitors interact at the S2-S3 subsites
with residues/groups that are in 2,3 positions of the inhibi-
tor, whereas the argatroban class of inhibitors achieve sim-
ilar interactions with their 1,3 residues. In both classes, the
chain direction in the active site is antiparallel to the main-
chain Ser214-Gly216 segment of thrombin, in contrast to the
natural inhibitor hirudin, where a parallel (3-strand is formed
(Rydel et al., 1990, 1991; Grutter et al., 1990). Hirudin, how-
ever, exhibits the argatroban-like 1,3 binding mode through
main-chain retro-binding (Tabemero et al., 1995).
Thiazole versus substrate-like binding at the Si' subsite
The 2-benzothiazole in RWJ-50353 and 2-ketothiazole in
RWJ-50215 bind at the S 1' subsite of thrombin. There they
are surrounded by His57, Tyr6OA, Trp6OD ("backside"),
and Lys6OF, and, in the case of RWJ-50215, by the piper-
idine ring of the ligand (Fig. 4). This cavity, first inferred as
the S ' subsite from the position of the glycine linker of the
divalent thrombin-hirulog 3 complex (Qiu et al., 1992), has
subsequently been verified by the structures of similar com-
plexes with hirutonin 2, hirutonin 6 (Zdanov et al., 1993),
and CVS995 (Krishnan et al., 1996). Although the benzo-
thiazole and thiazole rings bind to the Si' subsite, their
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FIGURE 3 Stereo view of omit electron density of the RWJ inhibitors in their bound state. (a) RWJ-50353; (b) RWJ-50215. Basket contours at 1 sigma.
Pertinent active site residues are as in Fig. 1.
interactions are significantly different because of their dif-
ferent size and shape.
The P1' benzothiazole ring of RWJ-50353 has interac-
tions with the catalytic His57 residue and with the Tyr6OA-
Thr60I insertion loop of thrombin. The N3 atom of the ring
forms a direct hydrogen bond with His57NE2 (Table 2), and
the indole ring of Trp6OD stacks edge on to the benzothia-
zole ring (Fig. 4a). A similar hydrogen bond between
His57NE2 and a nitrogen atom of a benzoxazole ring has
been inferred in the crystal structure of a complex between
porcine pancreatic elastase and Ac-Ala-Pro-Val-2-benzox-
azole (Edwards et al., 1992). Although the oxygen and
nitrogen positions could not be distinguished in the quasi-
symmetrical benzoxazole ring, the nitrogen atom was posi-
tioned toward the His57, because the oxygen atom in the
benzoxazole ring is a w-donor atom and is not expected to
possess hydrogen bonding capability. Apart from stabilizing
the overall structure in the active site, the hydrogen bond
between the His57 and benzothiazole ring could aid in
delocalizing the positive charge of a protonated His57
through the heterocyclic ring to the hemiketal oxygen atom,
lending further stability to the transition state oxyanion. The
sulfur atom points away from the active site and has a
couple of close contacts with Glu192 (Table 2). The three
terminal side-chain atoms of Lys6OF move about 0.8 A
compared to Lys6OF in the thrombin-hirugen complex to
accommodate the bulky benzothiazole ring in the SI' site
(Fig. 5).
Both N3 and 0 of the 2-ketothiazole of the RWJ-50215
inhibitor form hydrogen bonds with the side chain of
Lys6OF (Figs. 4 b and 5). The latter is analogous to the
hydrogen bond involving the carbonyl oxygen of a linker
2834 Biophysical Journal
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FIGURE 4 Stereo view of the binding of the RWJ inhibitors with thrombin. (a) RWJ-50353 in bold lines; thrombin in thin lines; hydrogen bonds in dotted
thin lines; water positions in lowercase. (b) RWJ-50215 in bold lines; PPACK in medium; thrombin in thin; hydrogen bonds in dotted lines; water positions
in lowercase.
glycine in the hirulog 3-thrombin structure (Qiu et al.,
1992), although the oxygen positions are displaced by about
1.5 A. The NZ of Lys6OF also forms a hydrogen bond with
His 570, an interaction that is found in many other thrombin
structures. Because the 2-ketothiazole is linked to the pip-
eridine binding at S2, whereas the P1' glycine residues of
hirulog 3 and CVS995 are bonded to the P1 arginine, the
pathways to the Si' site are necessarily different (Fig. 5).
After the Lys6OF hydrogen bond, the thiazole ring forms a
herringbone arrangement with Trp6OD (Burley and Petsko,
1985), and the hirulog 3 chain goes off in a different
direction. The carbonyl oxygen of RWJ-50215 is also
linked to Leu410 and Gly193N through 0413 and 0418
(Fig. 4 b).
Natural thrombin substrates show a preference for resi-
dues with small side chains at the P1' position. The prefer-
ence of the S1' subsite of thrombin for small P1' residues,
such as glycine or serine (Lottenberg et al., 1983) was
postulated to be the result of the limited size of the subsite
due to the protruding Lys6OF residue (Qiu et al., 1992;
Stubbs and Bode, 1993). This may be related to the obser-
vation that in the hirulog 3-thrombin structure, the P1'
glycine adopts a conformation that would be disallowed for
any residue with a side chain. It seems, however, to be more
than a simple fitting of a residue into the cavity, because the
amino group of the Lys6OF forms a hydrogen bond with the
carbonyl oxygen atom of His57 in most cases, whether the
S 1' subsite is unoccupied or occupied by a small residue
like glycine in the hirulog 3-thrombin structure or the 2-ke-
tothiazole ring in the RWJ-50215 structure. A bulkier group
at the P1' position, like the 2-benzothiazole in RWJ-50353,
causes the Lys6OF side chain to move away and disrupts the
2835Matthews et al.
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TABLE 2 Interactions of the inhibitors in the active site of
thrombin
Interactions Distance (A) Type
RWJ-50353
D-Phe
D-Phe
D-Phe
D-Phe
D-Phe
D-Phe
D-Phe
D-Phe
D-Phe
Pro
Pro
Pro
Arg
Arg
Arg
Arg
Arg
Arg
Arg
CZ-GLu97A 0
CEl-Tyr6OA OH
CD2-Ilel74 CD1
CD2-Ile215 CE3
CD2-Ile215 CG
CD2-Ile215 CB
CD2-Ile215 CD2
N-Gly216 0
O-Gly216 N
CB-His57 CD
CB-Trp6OD CH2
CG-Tyr60A CE2
C-Serl95 OG
NH1-AspI89 ODI
NH2-Aspl89 OD2
O-Glyl 93 N
O-Serl95 N
NH1 -Gly219 0
NE-Ow41 1-Glu 192 OE2
Arg NH2-Ow400-Phe227 0
Arg NHl-Ow411-Gly219 0
Ben N3-His57 NE2
Ben SI-GluI92 CA
Ben SI -GluI92 CB
Ben Sl-GlyI93 N
Ben C4A-His57 CD2
Ben C4A-His57 NE2
Ben C7A-Trp6OD CZ3
Ben C7-Trp6OD CZ3
Ben C6-Trp6OD CZ3
Ben C6-Trp6OD CE3
Ben C6-Lys6OF NZ
Ben C5-Trp6OD CZ3
Ben C4-His57 0
Ben C4-His57 CD2
Ben C4-His57 NE2
RWJ-50215
Dan Ol-Gly216 O
Dan SI -Gly216 O
Dan C2-Tyr6OA OH
Dan C3-Tyr6OA OH
Dan C2-Glu97A 0
Dan Cl l-Leu99 CG
Dan Cl 1-Leu99 CD2
Dan C1 I-Leu99 CD1
Dan C7-Trp2l5 CE3
Dan C7-Trp2l5 CD2
Dan C8-Trp2I5 CZ3
Dan C8-Trp2I5 CE3
Dan C8-Gly216 C
Dan C8-Gly216 0
Dan C8-Glu2l7 CG
Dan C9-Gly216 C
Dan C9-Gly216 0
Arg O-Gly216 N
Arg N-Gly216 0
Arg NHI-Asp 1890D1
3.7
3.7
3.7
3.5
3.5
3.6
3.6
2.9
3.0
3.9
3.9
3.9
van der Waals
H-bond
H-bond
van der Waals
1.8 Transition state
bond
2.6 H-bonded ion pair
2.7 H-bonded ion pair
2.7 H-bond
2.9 H-bond
2.8 H-bond
2.7,2.8 H-bonded solvent
bridge
2.9,3.0 H-bonded solvent
bridge
3.2,2.4 H-bonded solvent
bridge
2.7 H-bond
3.8
3.9
3.4
3.8
3.7
3.8
3.7
3.7
3.9
3.5
3.8
3.9
3.6
3.9
3.3
3.6
3.4
3.3
3.5
3.9
3.6
3.4
3.5
3.9
3.9
3.4
3.5
3.9
3.9
3.8
3.2
3.0
2.5
3.2
van der Waals
van der Waals
H-bond
H-bond
H-bonded ion pair
TABLE 2-continued
Interactions Distance (A) Type
RWJ-50215
Arg NH 1-Asp 1890D2 2.9 H-bonded ion pair
Arg NH2-Ow4090-Ser 3.2,2.7 H-bonded solvent
1950G bridge
Ow4090-2140 2.7 H-bond
Arg NH2-Ow3950-Phe 2270 3.2,2.9 H-bonded solvent
bridge
Arg NH1-Ow4710-Gly 2190 2.9,3.1 H-bonded solvent
bridge
Pip C2-Leu99 CB2 3.6
Pip C2-Trp2l5 CB 3.8
Pip C3-Leu99 CB2 3.5
Pip C3-Tyr6OA CZ 3.9
Pip C3-Tyr6OA CEI 3.9
Pip C4-Tyr6OA (all atoms) 3.7-3.9 van der Waals
Pip C4-His57 CD2 3.8
Pip C5-Trp60D CH2 3.5
Pip C5-Trp6OD CZ3 3.6
Tzl S1-Trp6OD CZ3 3.6
Tzl C4-Trp60D CZ3 3.1
Tzl C4-Trp60D CE3 3.6
Tzl N3-Lys60F NZ 3.0 H-bond
Tzl O-Lys6OF NZ 3.0 H-bond
Tzl O-Ow4130-Leu4lO 3.3,2.7 H-bonded solvent
bridge
Tzl O-Ow4180-Glyl93N 3.5,2.8 H-bonded solvent
bridge
hydrogen bond between His57 of the catalytic triad and
Lys6OF. That the interactions of Lys6OF appear to play an
important part in the biological activity of thrombin is in
agreement with the mutation of Lys6OF to glutamic acid,
which leads to a significant reduction of clotting activity
(Wu et al., 1991).
RWJ-50353 stnucture
As RWJ-50353 differs from PPACK only by the addition of
a benzothiazole ring at the P1' position, the overall inter-
actions between thrombin and RWJ-50353 are similar to
those in the thrombin-PPACK structure (rmsA = 0.52 A).
The inhibitor forms a hemiketal intermediate with the P1
arginine in the active site like PPACK. The carbonyl carbon
atom has tetrahedral geometry in the complex (ArgC-
Serl95OG 1.8 A), with the carbonyl oxygen atom posi-
tioned in the oxyanion hole. The OG oxygen impinges
nearly tetrahedrally on the carbonyl carbon atom of the
arginine (CA-C-O = 1090, OG-C-O = 113°, OG-C-C2-
Ben = 101°). The D-Phe-Pro-Arg motif has all of the
interactions previously observed in inhibitor-thrombin com-
plexes with this sequence binding in the active site (Table 2,
Fig. 4 a): the doubly hydrogen-bonded ion pair of the P1
arginine guanidinum group with Aspi 89 in the S1 specific-
ity pocket; the hydrophobic contacts with His57, Tyr6OA,
Trp6OD, and Leu99 in S2 apolar site by Pro; and the
formation of an antiparallel ,B-strand by the D-Phe-Pro-Arg
sequence with the Ser2l4-Gly216 of thrombin (Bode et al.,
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FIGURE 5 Stereo view of the Si'
binding site. RWJ-50353 in bold lines;
RWJ-50215 in medium; thrombin in
thin with Lys 60F of the RWJ-50353
structure in broken thin lines; hydrogen
bonds in dotted bold lines.
1992). The water structure in and around the active site is
conserved as in similar inhibitor-thrombin complexes
(Krishnan et al., 1996). The Glu192 residue is ordered in the
RWJ-50353-thrombin structure and interacts with arginine
of the inhibitor through a water-mediated hydrogen bond
(Glu1920E2-Ow41 1-ArgNE; Table 2).
RWJ-50215 structure
The interactions of RWJ-50215 with thrombin are similar to
those of argatroban, NAPAP, 4-TAPAP (Banner and Had-
vary, 1991; Brandstetter et al., 1992), and DAPA (Mathews
and Tulinsky, 1995). Like argatroban and DAPA, it binds in
a manner different from that of substrates, with CA of the
P1 arginine displaced from that in PPACK-thrombin by 4.1
A (Fig. 4 b). As a result, the arginine side chain forms a
three-center hydrogen-bonded ion pair in the SI site, in
which NH1 interacts with both ODI and OD2 of Asp189.
Most of the other interactions in the argatroban and DAPA
complexes are also retained in the present structure (Table
2): rms difference = 0.58 A with 32 equivalent atoms in
DAPA and 0.73 A with 30 atoms in MQPA. The backbone
N and 0 atoms of the P1 arginine hydrogen bond to Gly216
in an antiparallel manner.
Active-site water molecules mediate some additional
thrombin-inhibitor interactions, where Ow409 bridges the
NH2 group of arginine of the inhibitor with Serl950G and
Ser2140, and Ow395 connects the NH2 with Phe2270
(Fig. 4 b). The oxygen atom of Gly219 interacts with the
arginine side chain in two ways: by a hydrogen bond to the
NE atom and indirectly to NH2 through Ow471. A water
molecule in the DAPA-thrombin structure bridged a sulfo-
nyl oxygen of the dansyl group with Glu192 of thrombin.
L,4418 193
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The presence of a water molecule at this site in the RWJ-
50215 structure has not been confirmed.
The interactions of RWJ-50215 in the hydrophobic
S2-S3 sites of thrombin (Fig. 4 b) are also similar to those
of the argatroban structure. The dansyl group occupies the
hydrophobic S3 site bounded by Trp6OD and Ile174, and the
naphthalene ring forms a herringbone pattern with Trp215
(Burley and Petsko, 1985) in a way analogous to that of the
tetrahydroquinoline group of argatroban (Brandstetter et al.,
1992). The piperidine ring adopts a chair conformation and
binds at the S2 site surrounded by Leu99, His57, Tyr6OA,
and Trp6OD. The electron density cannot distinguish be-
tween two opposite orientations of the dansyl dimethyl-
amino substituent. Therefore, the methyl groups were ori-
ented to maximize hydrophobic interactions with the
naphthyl ring. The 4-ethylpiperidine group of DAPA makes
that inhibitor stronger and more selective than related com-
pounds (Okamoto et al., 1976). In RWJ-50215, the piperi-
dine ring is substituted at the 2 position with an alkyl bridge
to the ketothiazole group (Fig. 2) instead of a negatively
charged 2-carboxylate group, as in argatroban or the 4-ethyl
moiety of DAPA (Fig. 2). The electron density is consistent
with the linker group in the axial position, which gives R
stereochemistry at that carbon. The diastereomer with the
opposite hand showed reduced biological activity (Bruce E.
Maryanoff, private communication). The R configuration
was also observed in the argatroban structure (Brandstetter
et al., 1992).
The RWJ-50353 inhibitor binds much better to thrombin
(Ki = 0.16 nM) than does RWJ-50215 (Ki = 1.2 ,uM). A
number of factors contribute to the affinity of an inhibitor
for an enzyme (Beveridge and DiCapua, 1989). The resem-
blance of RWJ-50353 to natural substrates probably ac-
2837Matthews et al.
2838 Biophysical Journal Volume 71 November 1996
counts for some of the difference. The highly electron-
withdrawing benzothiazole group would be expected to
increase the electrophilicity of the arginine carbon atom,
leading to a stronger interaction with Serl95 OG (Costanzo
et al., 1996). However, other factors must also be involved,
because argatroban (Fig. 2), a molecule related to RWJ-
50215, is an excellent inhibitor of bovine thrombin, with a
Ki value of 14 nM (Kikumoto et al., 1984). Substituents on
the piperidine ring of argatroban make hydrophobic inter-
actions that are important in binding to the enzyme. A
molecule similar to argatroban, except for a 4-methyl group
on the piperidine ring, was a less potent inhibitor, with a K1
value of 310 nM. In contrast, removing only the 2-carbox-
ylate group caused a much smaller Ki increase to 30 nM,
whereas reversing the configuration at either carbon caused
large decreases in inhibition. A similar trend was observed
with DAPA (Kikumoto et al., 1980). A DAPA derivative
without the 4-ethyl substituent gave a 10-fold higher IC50
value (1.0 versus 0.1 ,uM) in a clotting assay. Because the
piperidine of RWJ-50215 occupies almost the same position
as in DAPA and argatroban, substitution at the 4 position
should lead to better inhibition. However, addition of the
ketothiazole and the flexible alkyl linker may increase the
entropy cost of binding RWJ-50215 to thrombin. Interest in
such compounds related to DAPA and argatroban is driven
by their nonpeptidic structures, by the much greater selec-
tivity these molecules show for thrombin over trypsin, plas-
min, and other proteases.
A survey of intramolecular arginine-carboxylate interac-
tions in protein structures (Singh et al., 1987) indicates that
the two specificity site arginine-aspartate geometries ob-
served in the RWJ-50353 and RWJ-50215 complexes are
not common. Twin N-twin 0 contacts, involving an arginyl
NH1 and NH2 as found in RWJ-50353, occurred only once
out of a total of 74 examples. Contacts involving NE and
NH1 of the arginine were more common with 16 cases, and
only four examples of three-center single N-twin 0 inter-
actions were found like those in RWJ-50215. Single N-
single 0 contacts were the most abundant, with 35 exam-
ples. It is difficult to reconcile the preference thrombin
shows for the least likely salt bridge structures, unless it is
related to the fact that its physiological specificity really
arises from binding at the fibrinogen binding exosite.
We would like to thank Dr. John W. Fenton II for samples of human
a-thrombin and the National Institutes of Health for grant HL25942 (AT).
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